US FDA Needs Plan For Addressing Inspection Backlog Post-COVID, GAO Says
Executive Summary
Agency must plan to ensure that a growing backlog of surveillance inspections does not impede its ability to conduct inspections at high-risk sites, GAO official says.
You may also be interested in...
US FDA Explores Pandemic Inspection Alternatives, Post-Pandemic Strategies
Agency's Janet Woodcock and Judy McMeekin say the FDA is looking at options like livestream plant videos while preparing to address backlog after inspections can resume.
US FDA Explores Pandemic Inspection Alternatives, Post-Pandemic Strategies
Agency's Janet Woodcock and Judy McMeekin say the FDA is looking at options like livestream plant videos while preparing to address backlog after inspections can resume.
Legislators Clamor For More Surprise FDA Inspections Abroad
House lawmakers who get the first cut at setting the FDA’s budget joined GAO expert in raising concerns about shortage of investigators and lack of surprise for foreign inspections.